New fact sheet: Regulatory authorities contribute to successful drug development

In recent years, the options for regulatory advice to pharmaceutical companies have expanded, with a particular focus on small and medium-sized enterprises (SMEs). In SwedenBIO's latest fact sheet, NDA Group gives tips on what advice the authorities can offer and what to consider before a meeting with the authorities.

– Whether the company intends to divest a project after a certain phase of development or plans to market its product itself, a clear strategy increases the interest of a potential partner, says Eva Lilienberg, Service Area Lead in the Global Development Unit.

– This saves the company time and money and ensures that the content of the documentation meets the requirements.

Through the fact sheets, SwedenBIO aims to provide practical information and advice in an area relevant to its members. More tips can be found in the factsheet here or at